DOCSLIB.ORG

Cphi China-Apis, Intermediates & Fine Chemicals.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Booth Number Company Name Company Introduction Main Products; Product Category Vitamin,Penicillin,Cephalosporins,Hormones,S ulfonamides,Lincomycin,Respiratory system drugs,Anesthetics,Other anti-infective Tournaire and their partners in Asia supply the API market drug,Other active pharmaceutical with packaging, equipment and products. With manufacturing ingredients,Plant extracts,Health care E1A01 Tournaire sites and engineering based in Europe we are a leading products Ingredient,Nutritional health company for technical solutions to most of the API majors on products Ingredient,Cosmetics the six continents. Ingredient,Food & beverage We are also involved in the Natural Extracts, Fine Chemicals Ingredient,Others,Anesthetic Preparation and and Bio-Chemical markets. Auxiliary Preparations,Vitamins, Minerals and Amino Acids Preparations,Others,Vaccines Anuh Pharma Ltd, Established in 1960, is part of 80 year’s old SK Group of companies. Main activity is into manufacturing of API’s, mainly Erythromycin Salts, Pyrazinamide, Azithromycin, Clarithromycin, Roxithromycin, E1A03 Anuh Pharma Sulfadoxine, Chloramphenicol Salts and Corticosteroids. Have regulatory approval for some of the products from EDQM, WHO Geneva, Cofepris (Mexico), Korean FDA etc. We have state of are R&D facility for building new generation API and process development. Vitamin,Tetracycline,Penicillin,Cephalosporins ,Hormones,Amino acids and derivatives,Aminoglycoside,Macrolides,Sulfon amides,Chloramphenicols,Lincomycin,Respira tory system drugs,Antipyretic Muromachi E1A04 analgesic,Digestive system Chemicals Inc drugs,Cardiovascular system drugs,Central nervous system drugs,Anesthetics,Other anti- infective drug,Antiparasitic,Other active pharmaceutical ingredients,Pharmaceutical Manufacturing,Export and Import of APIs; Muromachi is your Intermediates best choice! Pharmaceutical Intermediates,Fine Chemicals,Excipient,Surfactant,Transdermal As a worldwide leader in drug delivery system(DDS) enhancers,Stabilizing As a worldwide leader in drug delivery system(DDS) which which can improve therapeutic values of agent,Others,Intermediate can improve therapeutic values of pharmaceuticals, NOF pharmaceuticals, NOF continues to supply excellent Synthesis,Others,Antibody,Protein/Antigen/Pol E1A05 NOF Corporation continues to supply excellent products such as High-Purity products such as High-Purity Activated-PEG for PEG- ypeptide,Protein purification,Protein Activated-PEG for PEG-drug, Ultra-pure polysorbate 80 for drug, Ultra-pure polysorbate 80 for injection, High- modification,Enzyme,Nucleic acid/Protein injection, High-Purity Phospholipid for liposome. <M-PEG- Purity Phospholipid for liposome. <M-PEG-aldehyde, synthesis,Nucleic acid purification,cDNA and aldehyde, M-PEG-Maleimide, M-PEG-NHS, Branched-PEG,, M-PEG-Maleimide, M-PEG-NHS, Branched-PEG,, synthetic & purification,RNAi Multiarm-PEG, DSPE-PEG, DOPC, DEPC, DPPC , DSPG,, Multiarm-PEG, DSPE-PEG, DOPC, DEPC, DPPC , technology,Chemical reagent,Vaccines PS80 etc> DSPG,, PS80 etc> Hormones,Amino acids and ScinoPharm offers a wide array of process R&D services and derivatives,Respiratory system API manufacturing capabilities designed to satisfy drugs,Antipyretic analgesic,Digestive system customers\' exact requirements and facilitate their rapid drugs,Cardiovascular system drugs,Central ScinoPharm market introductions. ScinoPharm specializes in process nervous system drugs,Other active E1A08 Taiwan Ltd R&D and the production of CGMP Active Pharmaceutical pharmaceutical ingredients,Anti-tumor Ingredients (APIs). ScinoPharm targets four market Preparations,Other Preparations,Process segments in the global pharmaceutical industry: Custom Research & Development,Formula Synthesis for early phase pharmaceutical activities, Generic Optimization,API Synthesis,Intermediate API manufacturing, Brand company outsourcing services, Synthesis,Drug Manufacturing,Others and Injectable plant facility for high potency cytotoxics. Vitamin,Tetracycline,Penicillin,Cephalosporins ,Hormones,Amino acids and derivatives,Aminoglycoside,Macrolides,Sulfon amides,Chloramphenicols,Lincomycin,Respira tory system drugs,Antipyretic analgesic,Digestive system drugs,Cardiovascular system drugs,Central nervous system drugs,Anesthetics,Other anti- infective drug,Antiparasitic,Other active pharmaceutical ingredients,Pharmaceutical Intermediates,Pesticide Intermediates,Animal drug intermediates,Fine Chemicals,Excipient,Disintegrants,Lubricants, E1A18 Azelis Glidant,Coating material,Plasticizer,Enteric- coated material,Surfactant,Menstruum,Antioxidant,Op acifier,Correctives,Sweetening agents,Essence,Colorant,Transdermal enhancers,Filtering aid,Fining agent,Preservative,Stabilizing agent,PH control agents ,Others,Plant extracts,Animal extracts,Health care products Ingredient,Chinese traditional medicine Ingredient,Functional food Ingredient,Nutritional health products Ingredient,Cosmetics Ingredient,Food & beverage Ingredient AZELIS - Your GMP partner for global sourcing and supply The EDQM (Council of Europe) is a key European organisation. The EDQM is involved in the harmonisation and co-ordination of standardisation, regulation and quality control Products and services: European Pharmacopoeia 8th Council of Euope- of medicines, blood transfusion, organ transplantation, Edition; Pharmeuropa; Pharmaceutical Reference E1A19 Publisher,Others EDQM pharmaceuticals and pharmaceutical care, cosmetics and Standards; Blood Transfusion and Organ food and packaging. Products and services: European Transplantation Guides. Pharmacopoeia 8th Edition; Pharmeuropa; Pharmaceutical Reference Standards; Blood Transfusion and Organ Transplantation Guides. Sales of kosher products are growing at 15% every Sales of kosher products are growing at 15% every year in year in the world ； the world ； OU is the largest and most reliable kosher certifying OU is the largest and most reliable kosher certifying agency agency in the world; E1A20 Orthodox Union Others in the world; In the world, some 300 K products are OU certified ； In the world, some 300 K products are OU certified ； In USA,50% kosher products are certified by OU; In USA,50% kosher products are certified by OU; OU kosher symbol is the most recognized logo in the OU kosher symbol is the most recognized logo in the world. world. Vitamin,Tetracycline,Penicillin,Cephalosporins ,Hormones,Amino acids and Atovaquone derivatives,Aminoglycoside,Macrolides,Sulfon Nitazoxanide amides,Chloramphenicols,Lincomycin,Respira Clorsulon tory system drugs,Antipyretic Buparvaquone analgesic,Digestive system Toldimfos Sodium drugs,Cardiovascular system drugs,Central NGL Fine Chem Diminazene Diaceturate E1A21 nervous system drugs,Anesthetics,Other anti- Limited NGL Fine Chem Ltd manufactures APIs and Finished Triclabendazole infective drug,Antiparasitic,Other active Formulations for usage in Human & Veterinary health. Homidium Chloride pharmaceutical ingredients,Animal drug It exports to over 35 countries globally. It operates 3 cGMP Parvaquone intermediates,Others,Other facilities around Mumbai. Imidocarb Dipropionate Preparations,Process Research & Business Segments: APIs • Finished Formulation’s • Contract Nitroxynil Development,Formula Optimization,API Manufacturing & Custom Synthesis Butaphosphan Synthesis,Intermediate Synthesis,Drug Accreditations: WHO-GMP, ISO 9001:2008 & cGMP Amitraz Manufacturing,Others DIA E1A23 PHARMACEUTICA L CO., LTD. ROMPHARM E1A24 COMPANY Keystone E1A26 Pharmaceuticals, Inc. E1A32 Technovir The Searle E1A36 Company Limited Respiratory system drugs,Antipyretic analgesic,Digestive system drugs,Cardiovascular system drugs,Central nervous system drugs,Other active Hetero is a research based global pharmaceutical company pharmaceutical ingredients,Anti-tumor E1B01 Hetero Labs Limited focused on development, manufacturing and marketing of Preparations,Digestive System Active Pharmaceutical Ingredients (APIs), Intermediate Preparations,Nervous System Chemicals & Finished Dosages. Ever since its establishment Preparations,Urinary and Reproductive in 1993, Hetero showed a tradition of excellence and deep System Preparations,Cardiovascular sense of commitment in developing cost effective processes Preparations to offer wide range of affordable drugs. Sulfhydryl active reagents Fluorescent reagents Spin labels Nicotine derivatives and metabolites Neurochemicals Environmental standards, mutagens and metabolites Phthalates Retinoids Vitamin,Tetracycline,Penicillin,Cephalosporins Vitamin D derivatives ,Hormones,Amino acids and Drugs of abuse for forensic testing derivatives,Sulfonamides,Lincomycin,Pharma Phosphates Toronto Research ceutical Intermediates,Pesticide E1B02 Analytical Standards Chemicals Inc Intermediates,Animal drug intermediates,Fine Natural Products Chemicals,Plant extracts,Contract Amino Acids and peptides analysis/testing,Analysis and validation,API Toronto Research Chemicals Inc. Canadian company that Steroids Synthesis,Intermediate Synthesis manufactures and supplies research chemicals to the biotech APIs, impurities, and metabolites industry, government labs/research facilities, universities, and Stable isotopes labelled analogues the pharmaceutical industry. TRC manufactures and Building blocks distributes in excess of 55,000 products to more than 85 Chiral molecules countries. In February 2014, TRC acquired Synfine Carbohydrates and oligosaccharides Research Inc., located in Richmond Hill. This acquisition Nucleic acid derivatives provided an additional 21,000 square foot production facility. Glycosidase
Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic

    This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic

    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
  • Specifications of Approved Drug Compound Library

    Specifications of Approved Drug Compound Library

    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
  • Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
  • Steroids Topical

    Steroids Topical

    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
  • Formulary Updates Effective January 1, 2021

    Formulary Updates Effective January 1, 2021

    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
  • Medication List

    Medication List

    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
  • Highlights of Prescribing Information

    Highlights of Prescribing Information

    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gastrointestinal Perforation: Increased risk in patients with certain GI These highlights do not include all the information needed to use disorders; Signs and symptoms may be masked (5.4) ® EMFLAZA safely and effectively. See full prescribing information for • Behavioral and Mood Disturbances: May include euphoria, insomnia, EMFLAZA. mood swings, personality changes, severe depression, and psychosis (5.5) • Effects on Bones: Monitor for decreases in bone mineral density with EMFLAZA® (deflazacort) tablets, for oral use EMFLAZA® (deflazacort) oral suspension chronic use of EMFLAZA (5.6) Initial U.S. Approval: 2017 • Ophthalmic Effects: May include cataracts, infections, and glaucoma; Monitor intraocular pressure if EMFLAZA is continued for more than 6 ---------------------------INDICATIONS AND USAGE--------------------------- weeks (5.7) EMFLAZA is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older (1) • Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids. Administer live- ----------------------DOSAGE AND ADMINISTRATION---------------------- attenuated or live vaccines at least 4 to 6 weeks prior to starting • The recommended once-daily dosage is approximately 0.9 mg/kg/day EMFLAZA (5.8) administered orally (2.2) • Serious Skin Rashes: Discontinue at the first sign of rash, unless the rash is • Discontinue gradually when administered for more than a few
  • Comparative Effects of Anti-Inflammatory Corticosteroids in Human Bone-Derived Osteoblast-Like Cells

    Comparative Effects of Anti-Inflammatory Corticosteroids in Human Bone-Derived Osteoblast-Like Cells

    Copyright ©ERS Journals Ltd 1998 Eur Respir J 1998; 12: 1327–1333 European Respiratory Journal DOI: 10.1183/09031936.98.12061327 ISSN 0903 - 1936 Printed in UK - all rights reserved Comparative effects of anti-inflammatory corticosteroids in human bone-derived osteoblast-like cells H. Namkung-Matthäi*, J.P. Seale**, K. Brown***, R.S. Mason* aa Comparative effects of anti-inflammatory corticosteroids in human bone-derived osteo- Depts of *Physiology and Institute for blast- like cells. H. Namkung-Matthäi, J.P. Seale, K. Brown, R.S. Mason. ©ERS Journals Ltd Biomedical Research, **Pharmacology and 1998. ***Pharmacy, University of Sydney, Aus- ABSTRACT: While effects of inhaled corticosteroids on serum markers of bone tralia. metabolism in normal and asthmatic subjects have been reported, there are little data Correspondence: R.S. Mason on the direct effects of these corticosteroids on end-organs such as bone. The results Dept of Physiology and Institute for Bio- presented here compare the effects of budesonide and its epimers (22S- and 22R- medical Research budesonide), fluticasone and dexamethasone on growth and differentiation of cul- University of Sydney tured human bone cells. NSW 2006 Osteoblast-like cells were cultured from human foetal bone chips grown to conflu- Australia ence and used at first subculture. Fax: 61 293512058 At concentrations of 10-11–10-7 M each corticosteroid (CS) caused a dose-dependent Keywords: Alkaline phosphatase decrease in [3H]thymidine incorporation into deoxyribonucleic acid (DNA), median bioactivity effective concentration (EC50): fluticasone (0.06 nM) >22R (0.26 nM) >22S (0.4 nM) bone-derived cells >budesonide (0.47 nM) >dexamethasone (1.5 nM).
  • MSM Chapter 1200 3/1/21

    MSM Chapter 1200 3/1/21

    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER February 23, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER /Jessica Kemmerer/ BACKGROUND AND EXPLANATION The DHCFP is proposing revisions to Medicaid Services Manual (MSM), Chapter 1200 – Prescribed Drugs, Appendix A, to reflect recommendations approved on October 22, 2020, by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Doxepine Topical, the addition of new prior authorization criteria for Zeposia® (ozanimod), addition of new prior authorization for Evenity® (romosozumab-aqqg), Prolia® (denosumab), Forteo® (teriparatide) and Tymlos® (abaloparatide) within a new combined osteoporosis agents section, and addition of new prior authorization criteria for Orilissa® (elagolix) and Oriahnn® (elagolix, estradiol, and norethindrone) within a new Gonadorpin Hormone Receptor (GnRH) Antagonist and Combinations section. Additionally, the DHCFP is proposing revisions to the existing prior authorization criteria for psychotropic medications for children and adolescents, and revision to the existing clinical criteria for Epidiolex® (cannabidiol). Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re- arranging of sections was necessary. These changes are effective March 1, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL N/A MTL N/A MSM Ch 1200 – Prescribed Drugs MSM Ch 1200 – Prescribed Drugs Background and Explanation of Policy Changes, Manual Section Section Title Clarifications and Updates Appendix A Psychotropic Added new policy language criteria on which specific Section N Medications for drug classes may bypass polypharmacy clinical criteria. Children and Adolescents Appendix A Reserved for Future Created a new section titled “Doxepin Topical.” Added Section W Use new prior authorization criteria for doxepin topical.